InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,186.33
(
-3.00%
)
US TECH 100
17,653.20
(
-1.65%
)
Dow Jones
38,703.27
(
-2.60%
)
Brent Oil
77.12
(
-0.06%
)
Bitcoin
55,703.50
(
3.18%
)
Post# of 252790
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120214
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151549

Thursday, 09/19/2013 2:54:57 PM

Thursday, September 19, 2013 2:54:57 PM

Post# of 252790
TauRx has enrolled 300 patients in first phase-3 AD trial:

http://finance.yahoo.com/news/taurx-achieves-milestone-global-phase-184400536.html

The Phase 3 trials of a tau aggregation inhibitor target 'tau tangles' in the brain, and could provide the first definitive data on a tau-based treatment that dissolves the tangles and slows or halts Alzheimer's disease. The first study is evaluating the use of LMTX in over 800 patients with mild to moderate Alzheimer's over a 15-month treatment period. The second study is evaluating the use of LMTX in up to 700 patients with mild Alzheimer's over an 18-month treatment period.

Will they PR each increment of 100 enrolled patients?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up